Follow The Filings

Johnson & Johnson

New Brunswick, NJ 7 processed 13Fs on this site, 2025 Q3 to 2026 Q3

  • $762M
  • 15 holdings
  • 2026 Q3
  • −4.6% QoQ
  • Top 5 89.3%

Portfolio

2026 Q3, filed 10/26/2026, top 12 of 15 holdings

Top 5 89.3%, top 10 98.8%

  1. PTGX, Protagonist Therapeutics 45.3%
  2. NBTX, Nanobiotix 23.0%
  3. MGTX, Meiragtx 9.6%
  4. RAPP, Rapport Therapeutics 7.9%
  5. CTNM, Contineum Therapeutics 3.5%
  6. CBRS, Cerebras Systems 3.0%
  7. Xencor 2.4%
  8. Legend Biotech 2.1%
  9. FATE, Fate Therapeutics 1.1%
  10. CVRX 0.9%
  11. PRCT, Procept Biorobotics 0.9%
  12. NMRA, Neumora Therapeutics 0.1%
  13. Other 0.2%

AUM over time

2026 Q3 $762M −4.6% QoQ
2025 Q3: $504M 2025 Q3: $504M
Q3 2025
2025 Q4: $555M, +10.1% QoQ 2025 Q4: $555M, +10.1% QoQ
Q4
2026 Q1: $652M, +17.5% QoQ 2026 Q1: $652M, +17.5% QoQ
Q1 2026
2026 Q2: $799M, +22.5% QoQ 2026 Q2: $799M, +22.5% QoQ
Q2
2026 Q3: $762M, −4.6% QoQ 2026 Q3: $762M, −4.6% QoQ
Q3

Book

2026 Q2 2026 Q1, filed 6 Aug, long equity only

Download CSV Download Excel All activity
PTGX, Protagonist Therapeutics 37.59% Hold 2,449,183 $122.58 $300M — —
NBTX, Nanobiotix 26.55% Hold 5,623,816 $37.70 $212M — —
MGTX, Meiragtx 11.23% Hold 6,641,064 $13.51 $90M — —
RAPP, Rapport Therapeutics 9.31% Hold 1,784,517 $41.67 $74M — —
CTNM, Contineum Therapeutics 4.06% Hold 1,979,173 $16.39 $32M — —
Legend Biotech 2.95% Hold 814,586 $28.88 $24M — —
CVRX 2.59% Hold 4,024,861 $5.14 $21M — —
Xencor 1.51% Hold 748,062 $16.10 $12M — —
CBRS, Cerebras Systems 1.48% New 53,586 $221.00 $12M +53,586 +$12M
FATE, Fate Therapeutics 1.14% Hold 3,379,064 $2.70 $9.1M — —
PRCT, Procept Biorobotics 1.01% Hold 357,939 $22.58 $8.1M — —
NMRA, Neumora Therapeutics 0.39% Hold 1,849,445 $1.70 $3.1M — —
Vor Biopharma 0.12% Hold 53,732 $18.41 $989K — —
LAB, Standard Biotools 0.03% Hold 311,967 $0.8227 $257K — —
ACET, Adicet Bio 0.02% Hold 22,779 $8.64 $197K — —

Exits / last held

Gone since 2026 Q1, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
RLYB, Rallybio 0.21% Exit 0 $8.97 $1.4M −152,901 −$1.4M
Nano-X Imaging 0.03% Exit 0 $2.27 $190K −83,554 −$190K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2026 Q1. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

5 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q3 15 $762M −4.6% 13F-HR 10/26/2026 000090445426000541
2026 Q2 15 $799M +22.5% 13F-HR 8/6/2026 000090445426000435
2026 Q1 16 $652M +17.5% 13F-HR 5/13/2026 000090445426000280
2025 Q4 17 $555M — RESTATEMENT 3/18/2026 000090445426000192
2025 Q4 17 $555M +10.1% 13F-HR 2/13/2026 000090445426000111
2025 Q3 20 $504M — RESTATEMENT 3/18/2026 000090445426000190
2025 Q3 20 $504M — 13F-HR 11/13/2025 000090445425000587

About

Johnson & Johnson

7 processed 13Fs on this site, 2025 Q3 to 2026 Q3

SEC filing name
JOHNSON & JOHNSON
Location
New Brunswick, NJ
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf